Moxifloxacin HCl (Synonyms: BAY 12-8039) |
Katalog-Nr.GC11114 |
Moxifloxacin HCl (BAY 12-8039) ist ein orales 8-Methoxychinolon-Antibiotikum zur Behandlung von akuter bakterieller Sinusitis, akuter bakterieller Exazerbation einer chronischen Bronchitis und ambulant erworbener LungenentzÜndung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 186826-86-8
Sample solution is provided at 25 µL, 10mM.
Moxifloxacin HCl is anti-infective compound with a broad antibacterial spectrum.[1]
Moxifloxacin is a fourth generation fluoroquinolone antibacterial agent with a broad antibacterial spectrum against Gram positive bacteria and Gram negative bacteria in vitro.[1] The antibacterial activity of moxifloxacin is from the inhibition effect of DNA topoisomerase II and topoisomerase IV which are involved in bacterial DNA replication, transcription, recombination and repair[2]. The oral bioavailability of moxifloxacin is absolutely good which can be up to 90%. There are no many potenti[al drug interactions because that moxifloxacin is not a inhibitor or substrate of the hepatic cytochrome P-450 isoenzyme system. Moxifloxacin had bacteriologic eradication rates about 90–97% and clinical success rates of 88–97%. The MIC90s of moxifloxacin for the ciprofloxacin-susceptible isolates were ≤0.6 μg/mL. The MIC90s of moxifloxacin for enterococci range from 1 to 4 μg/mL. The reported MIC90s of moxifloxacin for Haemophilus parainfluenzae are from 0.03 to 0.125μg/mL. The MIC90s of moxifloxacin for B. fragilisrange 0.25–4 μg/mL and 4 μg/mL for other bacteroides species. [3]
Moxifloxacin also inhibits hPON1 (human serum paraoxonase-1) enzyme activity with Ki value of 2.641±0.004 mM in vitro.[4]
References:
[1]. Cruz LA, Hall R: Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresis. J Pharm Biomed Anal 2005, 38(1):8-13.
[2]. Kamruzzaman M, Alam AM, Lee SH, Ragupathy D, Kim YH, Park SR, Kim SH: Spectrofluorimetric study of the interaction between europium(III) and moxifloxacin in micellar solution and its analytical application. Spectrochim Acta A Mol Biomol Spectrosc 2012, 86:375-380.
[3]. Culley CM, Lacy MK, Klutman N, Edwards B: Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001, 58(5):379-388.
[4]. Turkes C, Soyut H, Beydemir S: Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem 2014:1-7.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *